Calypso Enters into Agreement to Be Acquired by Novartis
09-Jan-2024 -
Calypso Biotech BV, a leader in the development of Interleukin15 (IL-15) targeted therapies, announced that it has entered into an agreement to be acquired by Novartis AG. Calypso’s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development ...
acquisitions
autoimmune diseases
interleukin 15
+2